dc.contributor.author | Cui, W | |
dc.contributor.author | Yousaf, N | |
dc.contributor.author | Bhosle, J | |
dc.contributor.author | Minchom, A | |
dc.contributor.author | Nicholson, AG | |
dc.contributor.author | Ahmed, M | |
dc.contributor.author | McDonald, F | |
dc.contributor.author | Locke, I | |
dc.contributor.author | Lee, R | |
dc.contributor.author | O'Brien, M | |
dc.contributor.author | Popat, S | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-03-07T10:44:00Z | |
dc.date.available | 2023-03-07T10:44:00Z | |
dc.date.issued | 2020-01-01 | |
dc.identifier | 100261 | |
dc.identifier | S2468-2942(20)30096-4 | |
dc.identifier.citation | Cancer Treatment and Research Communications, 2020, 25 pp. 100261 - | |
dc.identifier.issn | 2468-2942 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5711 | |
dc.identifier.eissn | 2468-2942 | |
dc.identifier.eissn | 2468-2942 | |
dc.identifier.doi | 10.1016/j.ctarc.2020.100261 | |
dc.description.abstract | BACKGROUND: UK COVID-19 mortality rates are amongst the highest globally. Controversy exists on the vulnerability of thoracic cancer patients. We describe the characteristics and sequelae of patients with thoracic cancer treated at a UK cancer centre infected with COVID-19. METHODS: Patients undergoing care for thoracic cancer diagnosed with COVID-19 (RT-PCR/radiology/clinically) between March-June 2020 were included. Data were extracted from patient records. RESULTS: Thirty-two patients were included: 14 (43%) diagnosed by RT-PCR, 18 (57%) by radiology and/or convincing symptoms. 88% had advanced thoracic malignancies. Eleven of 14 (79%) patients diagnosed by RT-PCR and 12 of 18 (56%) patients diagnosed by radiology/clinically were hospitalised, of which four (29%) and 2 (11%) patients required high-dependency/intensive care respectively. Three (21%) patients diagnosed by RT-PCR and 2 (11%) patients diagnosed by radiology/clinically required non-invasive ventilation; none were intubated. Complications included pneumonia and sepsis (43% and 14% respectively in patients diagnosed by RT-PCR; 17% and 11% respectively in patients diagnosed by radiology/clinically). In patients receiving active cancer treatment, therapy was delayed/ceased in 10/12 (83%) and 7/11 (64%) patients diagnosed by RT-PCR and radiology/clinically respectively. Nine (28%) patients died; all were smokers. Median time from symptom onset to death was 7 days (range 3-37). CONCLUSIONS: The immediate morbidity from COVID-19 is high in thoracic cancer patients. Hospitalisation and treatment interruption rates were high. Improved risk-stratification models for UK cancer patients are urgently needed to guide safe cancer-care delivery without compromising efficacy. | |
dc.format | Print-Electronic | |
dc.format.extent | 100261 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Elsevier BV | |
dc.relation.ispartof | Cancer Treatment and Research Communications | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Covid-19;LUng cancer | |
dc.subject | Thoracic cancer | |
dc.subject | Adult | |
dc.subject | COVID-19 | |
dc.subject | Critical Care | |
dc.subject | Female | |
dc.subject | Hospitalization | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | SARS-CoV-2 | |
dc.subject | Thoracic Neoplasms | |
dc.subject | United Kingdom | |
dc.title | Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-11-30 | |
dc.date.updated | 2023-03-07T10:28:31Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.ctarc.2020.100261 | |
rioxxterms.licenseref.startdate | 2020-01-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33310368 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/The Adult Drug Development Unit at the ICR and the RM | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Lung Radiotherapy | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.ctarc.2020.100261 | |
pubs.volume | 25 | |
icr.researchteam | Adult DDU ICR & RM | |
dc.contributor.icrauthor | Minchom, Anna | |
icr.provenance | Deposited by Merina Ahmed on 2023-03-07. Deposit type is initial. No. of files: 1. Files: Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19) Single UK in.pdf | |